Pyocin efficacy in a murine model of <i>Pseudomonas aeruginosa</i> sepsis

Abstract

Pyocins S5 and AP41 show in vivo biological activity and can improve survival in two models of P. aeruginosa infection. They hold promise as novel antimicrobial agents for treatment of MDR infections with this microbe.